butenafine has been researched along with Leishmaniasis, Mucocutaneous in 1 studies
butenafine: studied on experimental dermatophytosis
butenafine : Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.
Leishmaniasis, Mucocutaneous: A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bezerra-Souza, A | 1 |
| Yamamoto, ES | 1 |
| Laurenti, MD | 1 |
| Ribeiro, SP | 1 |
| Passero, LF | 1 |
1 other study available for butenafine and Leishmaniasis, Mucocutaneous
| Article | Year |
|---|---|
The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
Topics: Animals; Antifungal Agents; Antiprotozoal Agents; Benzylamines; Drug Repositioning; Female; Leishman | 2016 |